Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the transaction, the chief executive officer directly owned 194,309 shares in the company, valued at $19,221,046.28. The trade was a 9.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, July 6th, Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $122.27, for a total transaction of $2,445,400.00.
• On Monday, June 1st, Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00.

Mirum Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ MIRM traded down $0.47 during mid-day trading on Tuesday, reaching $98.23. The company had a trading volume of 579,012 shares, compared to its average volume of 897,826. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. Mirum Pharmaceuticals, Inc. has a twelve month low of $63.23 and a twelve month high of $130.00. The stock’s 50 day moving average is $110.38 and its 200-day moving average is $101.91. The stock has a market capitalization of $6.38 billion, a PE ratio of -6.75 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same period in the previous year, the business posted ($0.12) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% on a year-over-year basis. As a group, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -4.42 earnings per share for the current fiscal year.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Comerica Bank raised its stake in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. AQR Capital Management LLC boosted its position in Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP acquired a new position in Mirum Pharmaceuticals during the first quarter valued at approximately $217,000. Finally, Empowered Funds LLC grew its holdings in Mirum Pharmaceuticals by 15.4% during the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Morgan Stanley set a $137.00 price target on Mirum Pharmaceuticals in a research note on Thursday, August 6th. Robert W. Baird set a $123.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Wolfe Research began coverage on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 target price for the company. HC Wainwright decreased their target price on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Finally, Citizens Jmp dropped their price target on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $137.33.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.